Mo-Sci makes glass products for medical devices. [Photo courtesy of Mo-Sci]
Mo-Sci is a supplier of glass microspheres, fibers and powders for medical devices, while ETS is the developer of bioactive glass fiber wound care product Mirragen, an FDA-cleared resorbable synthetic skin substitute.
The companies — both in Rolla, Missouri — will join Hanau, Germany-based Heraeus Group’s healthcare and medical technology portfolio. The deal is anticipated to close by the end of 2021.
“Across every treatment area, medical technology is changing rapidly,” Heraeus Head of Business Area Medical Technologies Nicolas Guggenheim said in a news release. “The acquisition of Mo-Sci and ETS gives us new capabilities to help our customers deliver innovative technologies and breakthrough treatments that will improve outcomes and patient care.”
ETS Technology Holdings has developed synthetic, absorbable, bioactive glass fiber technology for wound care. [Photo courtesy of ETS Technology Holdings]
“Prior to his passing, Ted identified Heraeus as a preferred partner to take Mo-Sci and ETS to the next stage of development,” Mo-Sci and ETS owner Kimberly Day said in the news release. “I am glad to carry this vision through to completion.”
